MYC-MAX protein-protein interface (MYC-MAX)

The MYC-MAX protein-protein interface is a critical molecular surface formed by the heterodimerization of the MYC transcription factor and its obligate partner MAX. Both proteins possess a basic helix–loop–helix leucine zipper (bHLH-LZ) motif that mediates this dimerization, which is essential for binding to E-box elements in the promoters of a large number of genes involved in cell proliferation, growth, differentiation, apoptosis, and metabolism[1][2][3]. MYC alone has weak DNA-binding ability but, when dimerized with MAX, forms a potent transcriptional activator complex that regulates thousands of genes[1][2][3][4]. This interface is considered a high-value therapeutic target, especially in cancer, as MYC is often overexpressed or dysregulated in tumors. Despite being considered 'undruggable' due to the lack of well-defined binding pockets, several experimental strategies—including dominant-negative peptides/proteins such as Omomyc and small molecules—have been developed to block the MYC-MAX interaction. Disruption of the MYC-MAX interface suppresses oncogenic transcriptional activity and tumor growth in preclinical models, although safety concerns and specificity remain challenges for drug development[2][4].

Other names

MYC:MAX dimerMYC–MAX heterodimerc-MYC:MAX interfaceMYC/MAX

Direct inhibition of MYC-MAX dimerization, preventing DNA binding and transcriptional activation of target genes Disruption of oncogenic transcriptional programs by competitive inhibition (e.g., Omomyc acts as a dominant-negative mutant) Indirect inhibition through bromodomain inhibitors suppressing MYC-driven transcriptional activity (e.g., JQ1)